Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) hit a new 52-week high during trading on Tuesday . The stock traded as high as $65.64 and last traded at $64.40, with a volume of 337436 shares traded. The stock had previously closed at $66.00.
Neoleukin Therapeutics Stock Up 8.7 %
The firm has a 50 day moving average of $44.55 and a 200 day moving average of $39.09. The firm has a market cap of $653.16 million, a PE ratio of -20.55 and a beta of 1.11.
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
See Also
- Five stocks we like better than Neoleukin Therapeutics
- Compound Interest and Why It Matters When Investing
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- Investing in Travel Stocks Benefits
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Insider Buying Explained: What Investors Need to Know
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
